Throughout my career in the biotech industry I have been fortunate to work on a wide range of cutting edge projects to produce material for first in man studies, whether it be protein fragments, antibody conjugates, DNA, viral, whole cell bacterial vaccines as well as more “conventional” protein or antibody therapies. Throughout these projects , it has always been very apparent to me that the key factor as to why projects might succeed or fail is the people involved at all levels w...
